Mortality and Suicide Risk in Treatment-Resistant Depression: An Observational Study of the Long-Term Impact of Intervention

Bryan Olin¹*, Amara K. Jayewardene¹, Mark Bunker¹, Francisco Moreno²

¹Cyberonics, Inc, Houston, Texas, United States of America, ²Department of Psychiatry, The University of Arizona, Tucson, Arizona, United States of America

Abstract

Major depressive disorder is a common global disease that causes a significant societal burden. Most interventional studies of depression provide a limited assessment of the interventions on mortality and suicide risks. This study utilizes data from an observational registry of patients with major depressive disorder to determine the impact of intervention (vagus nerve stimulation or standard pharmacological/non-pharmacological therapy) and a latent factor, patient trajectory toward response, on mortality, suicide and suicidal ideation. A total of 636 patients were available for an intent-to-treat analysis of all-cause mortality, suicide and suicidal ideation. Patients treated with vagus nerve stimulation in addition to standard therapies experienced lower, but not statistically significant, all-cause mortality (vagus nerve stimulation 4.93 per 1,000 person-years vs. 10.02 per 1,000 patient years for treatment as usual) and suicide rates (vagus nerve stimulation 0.88 per 1,000 person-years vs. 1.61 per 1,000 patient years for treatment as usual). Treatment with vagus nerve stimulation produced a statistically lower relative risk of suicidal ideation 0.80, 95% confidence interval (0.68,0.95). Further, patients that responded to either treatment saw a 51% reduction in relative risk of suicidal behavior; relative risk and 95% confidence interval of 0.49 (0.41,0.58). In summary, we find that treatment with adjunctive vagus nerve stimulation can potentially lower the risk of all-cause mortality, suicide and suicide attempts.

Introduction

Major depressive disorder (MDD) is very common, affecting about 121 million people worldwide [1]. In the United States, the lifetime prevalence of MDD is approximately 16% and the 12-month prevalence is approximately 7% [2]. Treatment-resistant depression (TRD), an often more severe and/or more chronic subset of MDD, is characterized by failure to respond to multiple therapeutic interventions, including non-pharmacologic treatments [3]. The STAR*D trial [4], a NIMH funded, large scale prospective study of over 3000 outpatients with nonpsychotic MDD demonstrated that up to 35% of patients could be considered to have TRD.

Major depressive disorder, particularly the treatment-resistant form, is characterized by significant financial burden to the individual and society resulting from lost productivity of both the patient with TRD and any caregivers, as well as increased direct health care utilization, including utilization associated with suicide attempts and mortality [5,6]. Worldwide, MDD is the leading cause of years lived with disability and is projected to be the second leading cause of disability adjusted life-years (DALY) by 2020, where DALY measures the burden to the individual and society [7]. In addition, it is projected that self-inflicted injuries will be the 10th leading cause of death in 2020. Major depressive disorder and other comorbid psychiatric conditions have been shown to result in an average of 27 years of potential life lost, a measure of the risk of premature death [8]. A study in the United Kingdom observed that the average decrease in life expectancy for patients with recurrent major depressive disorder is 7 years lost for females and almost 11 years lost for males [9].

Most research on therapeutic interventions for MDD addresses the effectiveness and adverse events (including suicidality) associated with those treatments, with limited focus on mortality. Several studies examined excess mortality associated with major depressive disorder [8–16]. However, the patients in these studies often have a less chronic and less severe form of depression than patients with TRD or were in studies undertaken prior to the availability of the current generation of anti-depressants and new trends in polypharmacy, such as the addition of atypical antipsychotics or simulant medications to the standard antidepressant medication regimen. In addition, they were generally long-term community-
based, observational studies that did not evaluate the impact of a therapeutic intervention.

This report characterizes mortality and suicide risks associated with treatment-resistant depression from an observational study of comparing the performance of standard pharmacological and non-pharmacological therapies (TAU) to vagus nerve stimulation (VNS+TAU) therapy adjunctive to standard therapies.

VNS Therapy® consists of a small pulse generator surgically implanted in the chest that delivers intermittent stimulation (typically 30 seconds on, 5 minutes off) via an electrode partially wrapped around the left vagus nerve in the mid-cervical region; the electrical signals are in turn processed in the nucleus tractus solitarius and relayed to various regions of the brain [17–19].

VNS has demonstrated antidepressant activity in animal models of depression [20] and in epilepsy studies where improvement in patient moods was seen independent of its impact on seizure activity [21,22].

VNS therapy was first approved for the adjunctive treatment of drug-resistant epilepsy in 1993 (Europe) and 1997 (US). It was subsequently approved in 2003 (Europe) and 2005 (US) for the adjunctive long-term treatment of chronic or recurrent depression for patients who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments. For both indications, there are specific age restrictions associated with the US FDA approvals. The effectiveness of VNS Therapy in depression has been previously reported in the literature [23–31].

VNS Therapy has also been considered as a possible adjunctive treatment for traumatic brain injury (TBI). This signal was first noted in patients with post-traumatic epilepsy who were non responsive to surgery [32]. Subsequently, animal models of TBI have led to the theory that VNS may play a role in TBI, potentially mediated by its effects on the immune response [33,34]. VNS Therapy’s ability to modulate the inflammatory response in both animal models [34,35] and humans [36–39] could lead to approved applications in other immunologically mediated disease states.

Beyond the effects of VNS in the central nervous system, the modality has also been shown to have significant peripheral effects. Recently, a pilot study has been completed evaluating the effects of VNS Therapy in patients with congestive heart failure (CHF) [40]. Positive results in this pilot study led to larger feasibility study in CHF being undertaken and recently completed [41]. The positive effect in CHF has led to the postulation that VNS Therapy may have a positive impact in patients suffering from ventricular arrhythmias [42].

Methods

Objectives

This research uses the results of an observational study to characterize the all-cause mortality rate, suicide rate and rate of suicidal ideation in patients with TRD. These rates are then compared for two interventions, standard treatment-as-usual (TAU) pharmacotherapy, where all available therapeutic interventions are allowed, including electro convulsive therapy (ECT) and psychotherapy, and VNS Therapy adjunctive to treatment-as-usual pharmacotherapy (VNS+TAU).

Description of Procedures or Investigations Undertaken

The TRD Registry (NCT00320572) is an ongoing, post-market surveillance study required by FDA as a condition of approval of the treatment-resistant depression indication for VNS Therapy to evaluate long-term patient outcomes.

The study is an observational, open-label, longitudinal, multi-center (45 US centers) registry of 500 patients with TRD treated with VNS+TAU and 300 patients with TRD treated with TAU. Patients are followed for 60 months, until withdrawal from the study, death or study completion.

Data collected included patient demographics and medical (especially psychiatric) history, concomitant medications and medication history and measures of clinical effectiveness including the Clinical Global Impression Improvement (CGI-I) [43], Montgomery-Asberg Depression Rating Scale (MADRS) [44] and the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) [45]. Safety measures assessed included mortality, suicidal ideation and side effects. Mortality, including suicide, is assessed through long-term follow-up. Suicidal ideation is measured using the Assessment of Suicidality (AOS) and MADRS Item 10 (Score ≥4. “Probably better off dead. Suicidal thoughts are common, and suicide is considered as a possible solution, but without specific plans or intention.”). To ensure consistency in ratings, a central ratings group is used to rate patients for both the MADRS and AOS measures. Side effects were assessed using the Frequency, Intensity, and Burden of Side Effects-Rating (FIBSER) questionnaire [46].

Participants

Patients were eligible for inclusion in the TRD Registry if the following criteria were met:

- Patient diagnosed with a current major depressive episode according to DSM-IV-TR criteria.
- Patient has been in the current depressive episode for 2 years or longer, or has had at least 3 lifetime episodes including the current MDE.
- Patient has had an inadequate response to 4 or more adequate anti-depressive treatments.
- The patient has a Clinical Global Impression Severity of illness score (CGI-S) of moderately ill (score of 4) or greater.
- The patient must be able to provide informed consent and complete all forms.

Patients were excluded from the TRD Registry if they met one or more of the following criteria:

- Patient has a history of schizophrenia, schizoaffective disorder, any other psychotic disorder, or a current major depressive episode that includes psychotic features; or is currently psychotic.
- Patient is currently enrolled in a double blind investigational study.
- Patient has previously received VNS therapy.
- Patient has a history of rapid cycling bipolar disorder.

Ethics

The TRD Registry was approved by the Western Institutional Review Board (WIRB) as well as the following local Institutional Review Boards (IRB): Advocate HealthCare IRB (Park Ridge, IL), Baylor College of Medicine IRB (Houston, TX), Cedars-Sinai Institutional Review Board (CSMC IRB) (Beverly Hills, CA), Jamaica Hospital Medical Center IRB (Jamaica, NY), KU School of Medicine-Wichita Human Subjects Committee (Wichita, KS), Loma Linda University IRB (Loma Linda, CA), Medical College of Wisconsin Froedtert Hospital IRB (Milwaukee, WI), Medical University of South Carolina (Charleston, SC), New York State...
Psyiatric Institute IRB (New York, NY), NorthShore University Health System Research Institute IRB (Evaston, IL), Oregon Health and Science University Research Integrity Office (Portland, OR), Partners Human Research Committee (Boston, MA), SUNY Upstate IRB (Syracuse, NY), Sutter Health Central Area Institutional Review Committee (IRC) (Sacramento, CA), The University of Arizona IRB (Tucson, AZ), The University of Utah IRB Research Administration Building (Lake City, UT), University Hospitals Case Medical Center IRB (Cleveland, Ohio), University of Connecticut Health Center IRB (Farmington, CT), University of Massachusetts Medical School IRB (Worcester, MA), University of Mississippi Medical Center IRB (Jackson, MS), University of Pennsylvania IRB (Philadelphia, PA), University of Texas Health Science Center San Antonio IRB (San Antonio, TX), University of Texas Southwestern Medical Center IRB (Dallas, TX), Wake Forest University Health Sciences IRB (Winston-Salem, NC) and Washington University Human Research Protection Office (St. Louis, MO).

Informed consent was obtained from all enrolled patients.

Statistical Methods

Patient demographics and baseline characteristics were summarized using descriptive statistics for the patients in each clinical study. Summary statistics include N, mean, standard deviation, median, and range (minimum, maximum) for continuous variables. Frequencies and percentages are used for summarizing categorical variables.

Absolute risk of mortality or suicide and rate of suicidal ideation were quantified as the number of events divided by the total exposure time to treatment. In addition, time spent in a state of non-response, clinical benefit (MADRS percentage decrease from baseline greater than 25% but less than 50%) and response (MADRS percentage decrease from baseline of 50% or more) was determined.

Due to the observational nature of these data, stratification was used to control for potential confounding factors.

A simple stratified analysis was conducted for mortality and suicide based on age group at the time of latest follow-up or death (under 40, 40–65 and 65 and older). Standardized mortality ratios (SMR), the observed number of deaths in the study population divided by the expected number of deaths in the US population, were calculated. The expected number of deaths was determined from published age-specific US mortality and suicide rates (Tables III, 3 and 10 of reference [47]). A SMR that exceeds 1 indicates that the study population has excess mortality relative to the US population.

A model for propensity scores [48] was identified using stepwise logistic regression methods on the binary outcome of treatment assignment, VNS+TAU treated = 1, TAU treated = 0. The significance level to enter (0.3 and 0.2) and significance level to remain (0.35 and 0.1) in the model were varied to assess the impact of these factors on model choice. The model considered the potential confounders in Table 1 and their two-factor interactions. Balance was assessed by examining the F-tests (continuous variables) or Cochran-Mantel-Haenszel (dichotomous or polytomous variables). The propensity scores were stratified into quintiles 1–5.

A second stratified analysis of mortality and suicidal ideation was performed treating the propensity score quintiles as strata [48], thereby adjusting for baseline confounders. Finally, we stratified suicidal ideation by both propensity score quintiles and treatment response (non-response, clinical benefit and response).

For stratified analyses, crude rates and standardized rates were calculated using standard methods [49]. The treatment groups were standardized against overall exposure for the entire population of patients in the study. The Byar approximation for confidence intervals for rates and SMRs was used [49].

A more parsimonious approach was taken to estimate standardized rates and relative risks for suicidality, allowing the assessment of the impact of treatment and whether the patient’s outcome trajectory led to response or non-response. This involved fitting a marginal structural model [50] to the logarithm of the count of suicidal ideations with an offset of the logarithm of patient-years (converting the count to a rate) and explanatory variables of treatment (VNS+TAU or TAU), response (responder vs. non-responder) and the treatment by response interaction. Propensity scores were used as weights. The significance of the interaction was assessed if and non-significant was dropped from the final model. Confidence intervals for the relative rate ratios of suicidality of VNS+TAU compared to TAU and responders compared to non-responders are provided.

Two additional analyses were performed on medications and side effects. We examined patterns in changes in therapy over the course of the study to determine whether or not these differed between groups, which could indicate a potential bias. The FIBSER burden was tabulated longitudinally to determine if the side effect profile differed between the two groups. A score of 0–2 for burden of side effects is an acceptable side-effect burden usually requiring no treatment adjustment. A score of 3 or 4 indicates moderate side-effect burden that should be evaluated further and an adjustment such as a dose decrease considered. A score of 5 or 6 indicates a high burden warranting a change such as dose decrease, switching, or direct treatment of the side effect(s) [51]. Both analyses were qualitative in nature.

A significance level of 5% was used for all analyses. Statistical analysis was performed using SAS version 9.1.3 (SAS Institute, Cary, North Carolina) and Microsoft Excel.

Results

Patient Characteristics

Figure 1 describes the patient flow during the course of the study. A total of 719 patients were assessed for eligibility; 682 were determined eligible and were enrolled in the study at 45 sites. After completing the screening visit, patients selected VNS+TAU (373) or TAU (309) options based upon which they believed was the best medical treatment. In May 2007, after the study had started, the Center for Medicaid Services issued a ‘non-coverage’ decision for VNS in TRD. This limitation in access and reimbursement caused treatment arm changes by precluding some patients from being implanted with VNS Therapy. A total of 34 patients exited the study prior to supplying any baseline data. After accounting for exits prior to implant and cross-overs, all 335 patients treated with VNS+TAU and 301 patients treated with TAU are considered in the subsequent intent-to-treat analyses. Patients in the VNS+TAU group have been followed for an average of 3.2 years vs. 2.1 years for the TAU group.

Table 2 summarizes the baseline characteristics of the study participants by treatment group.

The two treatment groups are well balanced for age, gender and length of illness. However, several baseline characteristics show notable differences. Patients treated with VNS+TAU have a more severe disease state than patients in the TAU group; increased history of ECT utilization (58% vs. 45%), a greater number of previous medications tried (8.0 vs. 7.3) and greater rate of psychiatric hospitalizations (2.8 vs. 1.9). We note that the greater use of prior treatment trials (ECT and medications) in the
Table 1. Factors used for propensity score adjustment.

| Factor                                                   | Description                                      |
|----------------------------------------------------------|--------------------------------------------------|
| Age                                                      | Age at onset of depression                       |
| Age at first diagnosis of MDD                           | Ethnicity                                        |
| Gender                                                   | Height                                           |
| Weight                                                   | # depressive episodes in lifetime including current |
| # psychiatric hospitalizations in lifetime              | duration of illness                               |
| length of current depressive episode                     | # lifetime suicide attempts                       |
| # suicide attempts in current episode                   | # failed treatment courses                        |
| Electroconvulsive therapy history (Y/N)                 | Primary diagnosis                                 |
| Baseline CGI-S                                           | Baseline MADRS                                   |
| Baseline QIDS-SR                                         |                                                  |

VNS+TAU likely reflects that the majority chose VNS+TAU as a final alternative when all other treatments had failed. This more severe illness is corroborated with through baseline assessments of depressive illness as the MADRS and CGI-S.
scores for the VNS+TAU and TAU groups show clinically significant differences of 4 and 0.5 points, respectively. Further, the elevated rate of previous suicide attempts for the VNS+TAU group (2.1 vs. 1.2) is confirmed by the increased percentage of VNS+TAU patients who exhibit suicidal ideations at baseline as assessed by the Assessment of Suicidality (“Has the patient made a suicidal gesture or attempt since the last visit?” Yes or No) (8.5% vs. 1.5%).

To further assess the comparability of the two treatment groups, we examined medical history (Table S1) and family history of drug abuse and psychiatric illness (Table 3).

The percentage of patients with histories of various illnesses was similar for the VNS+TAU and TAU groups. The exceptions were that the VNS+TAU group had a greater percentage of patients with current diagnoses of irritable bowel syndrome, hyperthyroidism and irregular heart rates at baseline. Both irritable bowel syndrome and hyperthyroidism are chronic health conditions that can be co-occurring with depression and can exacerbate symptoms and complicate a patient’s response to treatment. The higher baseline prevalence of irregular heart rates in the VNS+TAU treatment group may have increased the risk for cardiac death. This may have been mitigated by the potentially cardio-protective impact of vagus nerve stimulation noted earlier.

The TAU group had a greater percentage of patients with current diagnoses of cancer. One of the patients with a diagnosis of thyroid cancer did in fact die from liver cancer during the study.

However, none of these issues would likely have impacted or biased measures of suicidality.

Similarly, we identified no significant trends in the family history of substance abuse and psychiatric illness that would indicate any differences between treatment groups.

The propensity score model resulted in a model utilizing terms for race (Caucasian vs. Other), length of current depressive episode, number of lifetime suicide attempts, ECT history [yes or no], baseline scores for the CGI-S, MADRS and QIDS-SR and two factor interactions between baseline CGI-S and ECT history and baseline QIDS-SR and the number of lifetime suicide attempts. None of the Cochran-Mantel-Haenszel or F-tests comparing treatments or treatment by propensity score quintile interaction were significant indicating that subclassification by propensity score quintile was effective in removing bias.

Table 4 shows the number of patients per propensity score quintile along with the demographic characteristics. Basic demographic characteristics are similar. Note the marked gradation of disease state severity from propensity score quintile 1 to quintile 5 and that this composite measure confirms that the more severely ill patients were assigned to VNS+TAU.

Significant increases across quintiles can be seen for hospitalizations, suicidality (prior attempts during lifetime and current episode, as well as the percentage of suicidal patients at baseline) and baseline assessments (CGI-S, QIDS-SR and MADRS). Note also that the percentage of patients with a bipolar diagnosis increases with propensity score quintile.

### Outcomes

Table 5 summarizes all-cause mortality and suicide rates in the two treatment groups, overall and by age; both crude and standardized rates are provided, along with an analysis by each group. The standardized all-cause mortality (4.46 vs. 8.06 per 1,000 person years) and suicide rates (0.88 vs. 1.61 per 1,000 person-years) for patients treated with VNS+TAU are about half that of the patients treated with TAU alone, but they are not statistically lower due to the low mortality rate in both groups. Similar results were noted when stratifying by propensity score quintile.

We note that most of the patient deaths occurred in the 40–65 age group. Overall excess mortality, as measured by the SMRs in Table 5, indicates that there appears to be no excess all-cause mortality relative to the US population; the 95% confidence
intervals for the SMR contain one for both treatment groups; VNS+TAU: 0.53 (0.17,1.23) and TAU: 0.81 (0.26,1.88).

In contrast, as expected, both groups have a significantly elevated rate of suicide relative to the US population, approximately 6 times as great for the patients treated with VNS+TAU, 5.72 with 95% confidence interval (0.07,31.82), and 10 times as great for patients treated with TAU alone, 9.98 with 95% confidence interval (0.13,55.55). These results are similar to, if not slightly lower than, previous reports in similar populations of patients suffering from chronic depression.

Because the two treatment groups were well-matched on age, the more meaningful analysis is to stratify on the basis of propensity score quintiles to allow adjustment for other baseline confounders. Table 6 summarizes the stratified analysis of all-cause mortality and suicidal ideation as measured by both the Assessment of Suicidality and MADRS Item 10 score. A similar

### Table 4. TRD Registry Baseline Demographics and Clinical Data by Propensity Score Quintile.

| Propensity Score Quintile¹ | Baseline Demographics | 1 | 2 | 3 | 4 | 5 |
|---------------------------|-----------------------|---|---|---|---|---|
| (N = 122; 22/100²)        | (N = 122; 54/68)      | (N = 122; 68/54) | (N = 122; 85/37) | (N = 122; 98/24) |
| Age (Yrs.)                | 50.3±11.8             | 49.4±11.23        | 51.5±10.2        | 47.6±9.5         | 47.8±10.1        |
| % Female                  | 74.6%                 | 63.9%             | 65.6%            | 64.8%            | 74.6%            |
| % Caucasian               | 82.8%                 | 91.0%             | 99.2%            | 99.2%            | 97.5%            |
| Age of Onset (Yrs.)       | 20.6±11.4             | 20.8±10.7         | 22.3±12.5        | 21.1±13.0        | 20.4±11.9        |
| Age of First Diagnosis (Yrs.) | 29.1±11.9         | 29.3±10.2         | 32.0±11.8        | 28.0±11.7        | 28.5±10.7        |
| Length of Illness (Yrs.)  | 29.6±13.7             | 28.6±13.2         | 29.1±14.5        | 26.5±12.5        | 27.5±13.5        |
| Length of Current Episode (Yrs.) | 10.4±13.3        | 9.7±11.2          | 6.0±7.7          | 6.0±6.8          | 6.5±7.2          |
| % ECT History             | 11.5%                 | 62.3%             | 61.5%            | 71.3%            | 53.3%            |
| # Previous Drug Treatments | 6.2±2.4               | 7.6±3.3           | 8.2±2.8          | 8.3±3.3          | 7.8±3.0          |
| # Hospitalizations        | 0.9±2.1               | 1.7±2.6           | 2.2±6.3          | 3.1±6.6          | 4.0±6.0          |
| # Lifetime Suicide Attempts| 1.0±2.4               | 1.0±1.9           | 0.8±1.7          | 1.6±4.3          | 3.9±5.3          |
| # Current Suicide Attempts | 0.5±2.1               | 0.2±0.6           | 0.2±0.7          | 0.5±0.9          | 1.3±2.6          |
| Primary Diagnosis of Current MDE³ |                  |                |                |                |                |
| Major Depressive Disorder | 77.90%                | 78.70%           | 72.10%           | 69.70%           | 68.00%           |
| Bipolar Disorder          | 22.10%                | 21.30%           | 27.90%           | 30.30%           | 32.00%           |
| Baseline MADRS            | 26.7±6.8              | 28.1±7.7         | 30.8±5.4         | 33.7±6.5         | 37.6±6.8         |
| Baseline CGI Severity     | 4.1±0.2               | 4.6±0.6          | 4.9±0.5          | 5.4±0.6          | 5.8±0.7          |
| Baseline QIDS-SR          | 13.6±4.8              | 14.3±4.7         | 17.2±4.0         | 19.0±4.1         | 21.2±3.1         |
| Baseline % AOS⁴ Suicidal   | 3.3%                  | 3.3%             | 4.9%             | 7.4%             | 7.4%             |
| Total Person-Years        | 224.70                | 274.70           | 266.20           | 305.30           | 292.80           |

126 patients had missing values and propensity scores could not be calculated.
²Split between VNS and TAU patients, e.g., in quintile 1 there were 22 VNS+TAU and 100 TAU patients.
³MDE (Mood Disorder Episode).
⁴Assessment of Suicidality.

doi:10.1371/journal.pone.0048002.t004

### Table 5. Analysis of all-cause mortality and suicide rates, stratified by age: VNS+TAU and TAU TRD Registry Populations.

| Rate per 1,000 Person-Years with 95% Confidence Intervals | Standardized Mortality Ratio |
|----------------------------------------------------------|-----------------------------|
|                                                          | Crude          | Standardized | <40  | 40–64     | 65+          |
| VNS+TAU Population                                      |                |              |     |           |              |
| Total Person-Years                                      | 1,114.4        | 130.5        | 882.7 | 101.2     |
| All-Cause Mortality                                     | 4.49 (1.45,10.47) | 4.46 (0.00,9.41) | 7.66 (0.10,42.63) | 4.53 (1.22,11.60) | 0.00 (0.00,36.25) | 0.53 (0.17,1.23) |
| Suicide                                                 | 0.90 (0.01,4.99) | 0.88 (0.00,3.05) | 0.00 (0.00,28.11) | 1.13 (0.01,6.30) | 0.00 (0.00,36.25) | 5.72 (0.07,31.82) |
| TAU Population                                           |                |              |     |           |              |
| Total Person-Years                                      | 646.0          | 88.1         | 480.4 | 77.5      |
| All-Cause Mortality                                     | 7.74 (2.49,18.06) | 8.06 (0.00,16.99) | 0.00 (0.00,41.64) | 10.41 (3.35,24.29) | 0.00 (0.00,47.33) | 0.81 (0.26,1.88) |
| Suicide                                                 | 1.55 (0.02,8.61) | 1.61 (0.00,5.61) | 0.00 (0.00,41.64) | 2.08 (0.03,11.58) | 0.00 (0.00,47.33) | 9.98 (0.13,55.55) |

doi:10.1371/journal.pone.0048002.t005
analysis of suicide was not meaningful due to the small number of events, one in each group. The results are similar to stratification by age, the VNS+TAU group had a mortality rate of 4.93 per 1,000 person-years, 95% confidence interval of 0.00 to 15.60, half of the rate for the TAU group, 10.02 per 1,000 patient years, with 95% confidence interval of 0.00 to 31.03. Further, we note that over 50% of the total exposure to treatment for VNS+TAU occurs for patients in propensity score quintiles 4 and 5, the most severely ill patients, in contrast to only 25% for TAU.

Table 6 shows that suicidal ideation trends toward a higher rate at the more severe illness level. This is true with the MADRS Item 10 more so than for the Assessment of Suicidality, indicating that the MADRS Item 10 may be a more sensitive indicator of suicidal ideation and is better correlated with disease state. This is not surprising given that the likelihood of suicidal behavior was higher for patients in propensity quintiles 4 and 5, based on examination of the number of suicide attempts during the patients’ lifetime and current episode, lifetime as well as the assessment of suicidality.

Patients treated with VNS+TAU have a 10–20% reduction in the risk of suicidality as compared to patients treated with TAU alone for the MADRS Item 10, reaching significance with the marginal structural model (Table 7). In contrast, the Assessment of Suicidality is more variable and indicates that there is no statistically significant difference between treatment groups.

Table 7 shows the significant impact that response has on suicidal behavior. Response appears to be a stronger predictor of decreased suicidal behavior when included in the marginal structural model. As indicated in Table 7, patients who respond have a statistically significant 51% lower suicide risk than non-responders as measured by the MADRS Item 10; effects as measured by the standardized rates are even more pronounced. This is heavily weighted by the VNS+TAU group, which had the higher response rate, and a lower rate for decreased suicidal behavior, suicide and all-cause mortality. Even clinical benefit, having a 25–50% reduction in MADRS, appears to reduce suicidal behavior, as suggested by Table 8.

Given that TAU allowed for the use of any available therapy, we report in Table 9 the median, minimum and maximum number of times therapies were added, stopped or had dosage increases or decreases throughout the study per patient, for each treatment group. Examination of this table reveals that the profiles of therapeutic interventions were similar for both treatment groups, so opportunities for bias would be limited at best. Interestingly, we note that more patients in the VNS+TAU group were able to stop taking therapies than in the TAU group. Further study of this phenomenon is warranted.

Similarly, an examination of the side effect profiles as measured by the FIBSER (Table 10), shows that the percentage of unacceptable site effects for VNS+TAU is higher than TAU, but

Table 6. Analysis of mortality and suicidal ideation event rates per 1,000 person-years, as measured by the Assessment of Suicidality (AOS) and MADRS Item 10, stratified by propensity quintile.

| Rate per 1,000 Person-Years with 95% Confidence Intervals | Crude | Standardized |
|------------------------------------------------------------|-------|--------------|
| **VNS+TAU Population**                                     |       |              |
| Total Person-Years                                         | 1088.7|              |
| All-cause mortality                                        | 4.59  (1.48,10.72) | 4.93  (0.00,15.60) |
| Suicidal ideation (AOS)                                    | 64.30 (50.12,81.24) | 61.25 (0.00,125.87) |
| Suicidal ideation (MADRS Item 10)                          | 256.27 (227.08,288.17) | 234.27 (169.65,298.89) |
| **TAU Population**                                         |       |              |
| Total Person-Years                                         | 627.2 |              |
| All-cause mortality                                        | 7.97  (2.57,18.60) | 10.02 (0.00,31.03) |
| Suicidal ideation (AOS)                                    | 47.83 (32.27,68.29) | 47.28 (0.00,156.48) |
| Suicidal ideation (MADRS Item 10)                          | 204.08 (170.26,242.66) | 261.78 (152.57,370.98) |

| Rate per 1,000 Person-Years with 95% Confidence Intervals | 1     | 2     | 3     | 4     | 5     |
|-----------------------------------------------------------|-------|-------|-------|-------|-------|
| **VNS+TAU Population**                                    |       |       |       |       |       |
| Total Person-Years                                        | 79.6  | 177.2 | 227.8 | 297.0 | 307.1 |
| All-cause mortality                                       | 12.56 (0.16,69.90) | 0.00 (0.00,20.70) | 0.00 (0.00,16.10) | 10.10 (2.03,29.51) | 3.26 (0.04,29.51) |
| Suicidal ideation (AOS)                                   | 62.81 (20.24,146.59) | 50.79 (23.18,96.42) | 21.95 (7.07,51.22) | 43.77 (23.28,74.86) | 123.74 (87.55,169.85) |
| Suicidal ideation (MADRS Item 10)                         | 201.00 (114.82,326.44) | 95.94 (55.85,153.61) | 122.92 (61.66,177.65) | 296.30 (237.63,365.05) | 423.32 (353.67,502.66) |
| **TAU Population**                                        |       |       |       |       |       |
| Total Person-Years                                        | 186.5 | 167.4 | 116.6 | 88.4  | 68.3  |
| All-cause mortality                                       | 5.36  (0.07,29.88) | 0.00 (0.00,21.92) | 17.15 (1.93,61.93) | 11.31 (0.15,62.94) | 14.64 (0.19,81.46) |
| Suicidal ideation (AOS)                                   | 64.34 (33.21,112.40) | 17.92 (3.60,52.36) | 60.03 (24.05,123.70) | 67.87 (24.78,147.74) | 29.28 (3.29,105.72) |
| Suicidal ideation (MADRS Item 10)                         | 128.69 (84.43,191.48) | 95.58 (54.60,155.23) | 197.26 (125.00,296.00) | 429.86 (304.157,590.04) | 395.32 (260.45,575.19) |

1 Some patients had missing data at baseline leading to a missing propensity score.

doi:10.1371/journal.pone.0048002.t006

Mortality and Suicide Risk in TRD
that this difference dissipates over time. This is consistent with the experience in drug-resistant epilepsy and current product labeling [52,53].

Discussion

Key findings of our study were that patients treated with VNS+TAU experienced lower suicide risk and a potential signal toward decreased all-cause mortality rate. Additionally, the suicide and all-cause mortality rates in our study are generally consistent, or lower than, those reported in other large longitudinal studies of depression patients previously cited. Notably, the suicide rate for VNS+TAU is about half the standardized mortality rate observed in the TAU alone group. This lowered all-cause mortality rate is consistent with a recent report comparing patients with TRD in the US Medicare system treated with TAU (46.2 per 1,000 person-years) with patients treated with VNS+TAU (19.9 per 1,000 person-years) [54].

These data suggest that both response to (≥50% reduction in MADRS score) and partial clinical benefit (25 to 49% reduction in MADRS score) from VNS+TAU reduce the risk of suicidal behavior. Table 5 shows that the reduction in incidence of suicidal behavior is not restricted to responders but does occur for a continuum of antidepressant response for patients who show a partial clinical benefit. Most existing studies of depression therapies focus on response and remission of depressive symptoms as the primary clinical endpoints. This continues to be the appropriate gold standard; however, our study indicates that, in this treatment-resistant population, obtaining response or even moderate reduction of depression symptoms can effectively mitigate suicidal behavior.

These results were obtained in the backdrop of a unique study that includes a large number of patients with severe and chronic MDD who were followed for two to three years for two interventions. In contrast, most published data assessing interventions, generally pharmacotherapy, involve much shorter follow-up periods, usually one to two months and do not include TRD patients [16]. Studies with longer follow-up periods are observational cohort studies that aim to describe mortality and suicide rates and assess the impact of the disease state severity or demographic factors. The present study allows both objectives to be met: longer follow-up and assessment of the impact of a successful or unsuccessful therapeutic intervention has on mortality and suicide risk.

In addition, based on baseline CGI-S, QIDS-SR and MADRS scores, the patients in this study are more chronically and often more severely ill than many other patients studied in other papers previously referenced. For example, the average CGI-S across 207 anti-depressant trials is 4.1 to 4.6, as compared to the averages of 4.7 (TAU) and 5.2 (VNS+TAU) in our study [16]. Despite this difference in severity of illness, the suicide rate is less than that reported in most large series of monotherapy RCTs for the various

---

**Table 7. Relative rate ratio comparing suicidal ideation rates for VNS+TAU to TAU.**

| Relative Rate Ratios | Standardized | Marginal Structural Model: Treatment Only | Marginal Structural Model: Treatment and MADRS Response |
|----------------------|-------------|------------------------------------------|--------------------------------------------------------|
| VNS+TAU vs. TAU      |             |                                          |                                                        |
| AOS                  | 1.30 (0.79,2.14) | 1.44 (0.97,2.17) | 1.47 (0.97,2.24) |
| MADRS Item 10        | 0.89 (0.54,1.48)  | 0.80 (0.68,0.95) | 0.92 (0.77,1.09) |
| Response vs. Non-response |           |                                          |                                                        |
| AOS                  | 0.38 (0.13,1.06)  | NA                         | 0.88 (0.58,1.33) |
| MADRS Item 10        | 0.01 (0.00,0.14)  | NA                         | 0.49 (0.41,0.58) |

1Not Calculated (NC) and Not Applicable (NA).

doi:10.1371/journal.pone.0048002.t007

---

**Table 8. Analysis of suicidal ideation rates per 1,000 person-years, as measured by the Assessment of Suicidality (AOS) and MADRS Item 10, stratified by treatment response and propensity score quintile.**

| Rate per 1,000 Person-Years with 95% Confidence Intervals |
|----------------------------------------------------------|
| **VNS+TAU Population**                                   | **TAU Population**                                  |
| Total Person-Years                                       | Total Person-Years                                   |
| Crude Standardized                                      | Crude Standardized                                   |
| AOS                                                      | AOS                                                   |
| 88.90 (59.53,127.68)                                     | 58.32 (33.95,93.38)                                  |
| 76.02 (7.88,144.16)                                     | (50.00,124.57)                                       |
| 100.61 (63.76,150.98)                                   | 50.00 (0.00,124.57)                                  |
| 68.07 (0.00,190.09)                                     | 68.07 (0.00,190.09)                                  |
| 29.31 (13.37,55.64)                                     | 29.31 (13.37,55.64)                                  |
| 26.59 (0.00,65.00)                                     | (0.00,65.00)                                        |
| 705.09 (616.90,802.35)                                  | 397.94 (328.82,477.30)                               |
| 633.72 (426.50,840.94)                                  | 529.70 (296.43,762.96)                               |
| 205.60 (151.05,273.41)                                  | 100.00 (51.61,174.69)                               |
| 181.19 (64.02,298.37)                                   | 131.99 (0.00,305.52)                                 |
| 6.51 (0.73,23.51)                                      | 0.00 (0.00,40.62)                                   |
| 5.54 (0.00,22.42)                                      | 0.00 NC1                                              |

1NC: Not calculated both point estimates were 0, leading to a 0 standard error.
doi:10.1371/journal.pone.0048002.t008
medications used in patients treated in the TAU group. In addition, all available therapeutic interventions were allowed, including electro convulsive therapy (ECT) and psychotherapy, in the TAU group for this study.

The greater effect in treatment responders suggests that adjunctive VNS therapy may act synergistically with pharmacotherapy to improve depressive symptoms and decrease suicidal ideation, ultimately decreasing the incidence of suicide and premature death in patients with TRD. This is significant as the only other therapy associated with a similar reduction in suicidal ideation and suicide risk in patients with MDD, as well as bipolar disorder, is lithium as suggested by placebo-controlled trials [55] and a number of reviews [56,57].

Severely ill patients (5th propensity score quintile) also see a significant benefit from adjunctive VNS therapy, e.g., reduction in suicide risk. However, this reduction is not to the same degree as less severely ill patients, indicating that patients with a greater degree of illness severity may need an appropriate increase in frequency of physician follow up initially. This continued level of suicide risk is not surprising given that this group had twice the rate of suicide attempts and hospitalizations at baseline.

With respect to mortality rates, fortunately, only a small number of participants died during the study; details are provided in Table S2. This, combined with the variety of causes with several non-natural causes (homicide, suicide, accident) and several not known, precludes us from assessing if adjunctive VNS therapy leads to a decrease in mortality by natural causes potentially influenced by the vagal system. This limitation also prevented an assessment of whether mortality is dependent upon therapeutic response.

Although this is a limitation of the study at this time, it does provide an interesting potential signal to be explored as additional data are collected. The mechanism of action for such a potential may be solely related to differential antidepressant response between groups. Alternatively, it may indicate that adjunctive VNS therapy has particular clinical utility for patients with TRD who are at increased risk of mortality resulting from conditions modulated by the vagus nerve, such as patients with cardiac and vascular insufficiencies or immunologically compromised patients.

Given the current awareness of increases in all-cause mortality in patients with severe mental illness, the current study addresses an important outcome variable often ignored in prospective clinical trials and prospective observations. The findings of our study are thus significant both from the prospective of clinical

| Therapy                  | Number of Patients | Additions¹ | Stops | Decreased Dose | Increased Dose |
|--------------------------|--------------------|------------|-------|----------------|----------------|
| TAU                      | VNS+TAU            | TAU        | VNS+TAU| TAU            | VNS+TAU        |
| Antidepressant           | 283                | 314        | 0 (0 to 4) | 1 (0 to 5) | 0 (0 to 2) | 0 (0 to 3) | 0 (0 to 3) |
| Antiepileptic            | 137                | 205        | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) |
| Antipsychotic            | 4                  | 13         | None    | 0 (0 to 1) | 0 (0 to 1) | 0 (0 to 1) | 0 (0 to 1) |
| Anxiolytic               | 121                | 164        | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) |
| Atypical Antipsychotic   | 150                | 194        | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) |
| ECT                      | 24                 | 20         | 0 (0 to 1) | 1 (0 to 2) | NA           | NA           | NA           |
| Hypnotic                 | 126                | 146        | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) |
| Lithium                  | 40                 | 49         | 0 (0 to 2) | 1 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) |
| Psychostimulant          | 56                 | 83         | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) | 0 (0 to 2) |
| Therapy                  | 13                 | 15         | 1 (0 to 2) | 1 (0 to 2) | NA           | NA           | NA           |
| Thyroid Suppl.           | 39                 | 65         | 0 (0 to 1) | 0 (0 to 1) | 0 (0 to 1) | 0 (0 to 1) | 0 (0 to 1) |

¹The median, minimum and maximum number of therapeutic additions are provided; similarly for the analysis of therapies stopped, decreased or increased.

doi:10.1371/journal.pone.0048002.t009

| Visit (Month) | TAU | VNS+TAU |
|---------------|-----|---------|
|               | Acceptable (0-2) | Moderate (3-4) | Unacceptable (5-6) | Acceptable (0-2) | Moderate (3-4) | Unacceptable (5-6) |
| 0             | 76.5% | 19.4% | 4.1% | 64.3% | 29.9% | 5.7% |
| 3             | 79.3% | 18.0% | 3.6% | 73.4% | 21.5% | 5.1% |
| 6             | 76.8% | 20.6% | 2.5% | 79.5% | 15.6% | 4.7% |
| 9             | 71.4% | 14.0% | 4.7% | 76.8% | 19.2% | 4.1% |
| 12            | 76.7% | 18.0% | 5.4% | 74.6% | 21.6% | 3.9% |
| 18            | 86.2% | 10.2% | 3.6% | 74.1% | 22.4% | 3.5% |
| 24            | 75.4% | 20.1% | 4.4% | 76.8% | 21.0% | 2.1% |
| 36            | 86.0% | 10.0% | 4.0% | 81.4% | 14.4% | 4.2% |

doi:10.1371/journal.pone.0048002.t010
outcome as well as the public health burden imposed on society by these patients.

Limitations

The key limitations of this study are that it is non-randomized and observational in nature. In particular, selection bias was present as patients were allowed to choose their allocation to VNS+TAU or TAU which created the difference in disease severity between the two treatment groups; more severely ill patients were more likely to desire VNS+TAU as they had exhausted most other treatment options.

The impact of this selection bias was assessed via stratification and would have theoretically increased the likelihood of non-response, suicidal ideation, suicide and mortality in the VNS+TAU group due to the allocation of more severely ill patients.

Supporting Information

Table S1 TRD Registry Medical History Data. (DOCX)
Table S2 Baseline clinical detail on patient deaths. (DOCX)

Author Contributions

Performed the experiments: MB. Analyzed the data: AJ BO. Wrote the paper: BO AJ MB FM.

References

1. World Health Organization (2011) Depression. Available: http://www.who.int/mental_health/management/depression/definition/en/. Accessed: 2011 January 25.
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, et al. (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095–3105.
3. AHRQ (2011) Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Comparative Effectiveness Review Number 33.
4. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewert JW, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1909–17.
5. Greden JF (2001) The Burden of Disease for Treatment-Resistant Depression. J Clin Psychiatry 62(Suppl 16): 26–31.
6. Culpepper L (2011) Understanding the burden of depression. J Clin Psychiatry 72(6): e19.
7. Murray CJL, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. The Lancet 349: 1490–1502.
8. Colton CW, Manderscheid RW (2006) Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. Available: http://www.cdc.gov/pcd/issues/2006/apr/05_0110.htm Accessed: 2012 March 23.
9. Chang C-K, Hayes RD, Perera G, Broadbent MTM, Fernandes AC, et al. (2011) Life expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London. PLoS ONE 6(3): e19580. doi:10.1371/journal.pone.0019590.
10. Berglund M and Nilsson K (1987) Mortality in severe depression: A prospective study including 103 suicides. Acta Psychiatr Scand 76: 372–38.
11. O’Leary DA, Lee AS (1996) Seven year prognosis in depression: mortality and readmission risk in the Nottingham ECT cohort. Br J Psychiatry 169: 423–429.
12. Harris E.C., Barraclough B (1997) Suicide as an outcome for mental disorders. Br J Psychiatry 170: 203–228.
13. Harris E.C., Barraclough B (1996) Excess mortality of mental disorder. Br J Psychiatry 173: 11–53.
14. Shergill SS, Robertson MM, Steing R, Bernad M, Katona CLE (1999) Outcome in refractory depression. J Affect Disord 54: 287–294.
15. Bredbk L, Bergdul M (2001) Late mortality in severe depression. Acta Psychiatr Scand 103: 111–116.
16. Hammad TA, Laughren TP and Raccojin JA (2006) Suicide Rates in Short-term Randomized Controlled Trials of Newer Antidepressants. J Clin Psychopharmacol 26(2): 203–207.
17. Henry TR (2002) Therapeutic mechanisms of vagus nerve stimulation. Neurology. 59: 83–14.
18. George MS, Sackeim HA, Marangell LB, Husain MM, Z. Nahas Z, et al. (2000) Vagus nerve stimulation. A potential therapy for resistant depression? Psychiatr Clin North Am. 23: 757–783.
19. Nemeroff CB, Mayberg HS, Krahl SE, McNamara J, Frazer A, et al. (2006) Vagus nerve stimulation in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 31: 1345–1355.
20. Kralh SE, Semanayake SS, Fekary AE, Satin A (2004) Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action. J Psychiatr Res 38: 237–240.
21. Harchen CL, Pulver MC, Rasmussen P, Bach H, Beppler JP, Lobar DR (2000) A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav 1: 93–99.
22. Elger C, Hoppe C, Falkai P, Rush AJ, Elger CE (2000) Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsia. 42: 203–210.
23. Marangell LB, Rush AJ, George MS, Sackeim HA, Johnson CR, et al. (2002) Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry 51: 260–267.
24. George MS, Rush AJ, Marangell LB, Sackeim HA, Braman SK, et al. (2005) A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 50: 364–373.
25. Nahas Z, Marangell LB, Husain MM, Rush AJ, Sackeim HA, et al. (2003) Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depression episodes. J Clin Psychiatry 66: 1097–1104.
26. Rush AJ, Marangell LB, Sackeim HA, George MS, Braman SK, et al. (2005) Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 58: 347–354.
27. Rush AJ, Sackeim HA, Marangell LB, George MS, Braman SK, et al. (2005) Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 58: 355–363.
28. Sackeim HA, Braman SK, Rush AJ, George MS, Marangell LB, et al. (2007) Durability of antidepressant response to vagus nerve stimulation (VNS) [146]. Int J Neuropsychopharmacol 10: 817–828.
29. Bajouj M, Merkl A, Schlaepfer TE, Friek C, Zobel A, et al. (2010) Two-year outcome of vagus nerve stimulation in treatment-resistant depression. Journal of Clinical Psychopharmacology 30(3): 273–281.
30. Martin JLR, Martin-Sanchez E (2012) Systemic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. European Psychiatry 27: 147–155.
31. Danan C, Martinez-Arana A, Cruz N, Vieta E (2008) Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord 110(1–2): 1–15.
32. Lee HO, Koh EJ, Oh YM, Park SS, Kwon KH, et al. (2008) Effect of vagus nerve stimulation in post-traumatic epilepsy and failed epilepsy surgery: preliminary report. J Korean Neurosurg Soc 44: 196–198.
33. Kumar A and Tosfas CM (2012) Is there a role for vagus nerve stimulation therapy as a treatment of traumatic brain injury? British Journal of Neurosurgery 26(3): 316–320.
34. Lopez NE, Krzywaniek M, Costantini TW, De Maio A, Baird A, et al. (2012) Vagal nerve stimulation blocks periconal macrophage inflammatory response and prevents proinflammation after severe brain injury. J Trauma Acute Care Surg 72(6): 1362–1366.
35. Mihaylova S, Killion A, Mayer K, Pallmiter SS, Schermuly R, et al. (2012) Effects of anti-inflammatory vagus nerve stimulation on the cerebral microcirculation in endotoxinemic rats. J Neuroinflammation 25(8): 183. [Epub ahead of print].
36. Corcoran C, Connor TJ, O’Keane V, Garland MR (2005) The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report. Neuroimmunomodulation 12(5): 307–9.
37. Majoe JHM, Rijkers K, Bertello MW, Halmon JARJ, Miyaz T, et al. (2011) Vagus Nerve Stimulation in Refractory Epilepsy: Effects on Pro- and Anti-Inflammatory Cytokines in Peripheral Blood. Neuroimmunomodulation 18: 52–60.
38. Vagus Nerve Stimulation a New Approach in the Treatment of Crohn’s Disease (VNS), ClinicalTrials.gov Identifier: NCT01569503, Available: http://clinicaltrials.gov/ct2/show/NCT01569503, Accessed: 2012 August 29.
39. Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis, ClinicalTrials.gov Identifier: NCT01329914, Available: http://clinicaltrials.gov/ct2/show/NCT01329914, Accessed: 2012 August 29.
40. Schwartz JJ, De Ferraria GM, Sanio A, Landolima L, Rordorf R, et al. (2008) Long term vagal stimulation in patients with advanced heart failure: First experience in man. Eur J Heart Fail 10(3): 604–611.
41. De Ferraria GM, Cn主页 HJ, Bogdorge M, Milsanov M, Smalj J, et al. (2011) CardioFit Multicenter Trial Investigators. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 32(7): 647–55.
42. Brack KE, Winter J, Ng GA (2012) Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation-ventilatory prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failure. Heart Fail Rev. doi:10.1007/s10741-012-9351-2.
43. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare.

44. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–9.

45. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, et al. (2003) The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54: 573–583.

46. Winneke NE, Rush AJ, Balsubramani GK, Trivedi MH, Nierenberg AA (2006) Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 12: 71–79.

47. Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B (2010) Deaths: Final data for 2007. National Vital Statistics Reports; vol 58 no 19. Hyattsville, MD: National Center for Health Statistics.

48. Rosenbaum PR, Rubin DB (1984) Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. J Amer Stat Assoc 79: 516–524.

49. Rothman KJ, Greenland S and Lash TL (2008) Modern Epidemiology, 3rd edition. Oxford: Lippincott, Williams and Wilkins.

50. Sato T, Matsuyama Y (2003) Marginal Structural Models as a Tool for Standardization. Epidemiology 14(6): 680–686.

51. Trivedi MH (2007) Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry 70 Suppl 6: 26–31.

52. Morris GL 3rd, Mueller WM (1999) Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01–E05. Neurology. 53(9): 1731–3.

53. Part III - Depression Information VNS Therapy™ Pulse Generators. December 2008. Available: http://dynamic.cyberonics.com/manuals/, Accessed: 2012 August 29.

54. Friedman RL, Dunner DL, Muller JS, Stone DA (2012) Medicare Patient Experience with Vagus Nerve Stimulation for Treatment Resistant Depression. J Med Econ doi:10.3111/13696998.2012.724745.

55. Lauterbach E, Felber W, Muller-Oerlinghausen B, Ahrens B, Bronisch T, et al. (2008) Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand 118(6): 469–79.

56. Baldassarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, et al. (2006) Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 8(5 Pt 2): 625–39.

57. Guzzetta F, Tondo L, Centorrino F, Baldassarini RJ (2007) Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 68(9): 808–3.